• Home |
  • Careers |
  • Contact |
  • Subscription |
  • Site map |
  • Français |
  • Text size: A A A
Ambrilia Biopharma
  • About
    • + Vision & strategy
    • + Management
    • + Board of directors
    • + Scientific advisory board
  • Investors
    • + Presentations and webcasts
    • + Shareholder information
    • + Stock information
    • + Financial reports
    • + Corporate governance
    • + Analysts
    • + Sustainability
    • + Investor contact
  • News & Events
    • + News
    • + Events
    • + Media room
  • Pipeline
    • + Acromegaly - Octreotide
    • + Prostate cancer - PCK3145
    • + Prostate cancer - Goserelin
    • + Cancer - NGR-Delivery Technology
    • + HIV/AIDS - Protease Inhibitors
    • + HIV/AIDS - Integrase Inhibitors
    • + HIV/AIDS - Entry Inhibitors
    • + HCV - Polymerase Inhibitors
    • + HCV - Entry Inhibitors
    • + Influenza A - M2 Proton Channel Inhibitors
    • + Diagnostic - PSP94
    • + Diagnostic - Colopath® / ColorectAlert™
  • Scientific library
  • Partnerships
    • + Our partners
    • + Partnership / Divestment Opportunities

News & Events

  • + News
  • + Events
  • + Media room

Media room

Ambrilia in the Media

  • The Globe & Mail, Thursday, Sept. 11, 2008 - Insiders sense a bargain as buying heats up
  • The Gazette, August 12, 2008 - Ambrilia shifts focus to anti-virals (PDF)
  • The Gazette, July 29, 2008 - Merck puts HIV drug developement on hold (PDF)
  • The Gazette, July 22, 2008 - Ambrilia presses ahead with development (PDF)
  • GEN, March 15, 2008, Vol. 28, no.6 - Surmounting small molecule challenges (PDF)

Logos

Ambrilia GIF JPEG EPS Illustrator ALL
Ambrilia GIF JPEG EPS Illustrator ALL

Bio notes

  • Philippe Calais, Ph.D., Pharm., President and CEO

Photos

 

Documentation

  • Corporate Presentation (PDF 1.05 Mb)

Financial Reports

  • 2007 Annual Report
  • 2008 - Third Quarter (PDF 260 Kb)
 

Copyright © 1998-2009 Ambrilia Biopharma. All rights reserved. - Terms of use - Forward looking statement